Clinical trials: Cytomegalovirus Infection
Cytomegalovirus (CMV)
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with…
- Trial name
- NCT01611974
- Testing
- Maribavir
- Where
- 32 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shire
Cytomegalovirus (CMV) Infection, Kidney Transplantation
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative…
- Trial name
- NCT03629080
- Testing
- HB-101 vaccine
- Where
- 25 sites in United States, Denmark and 4 more
- Volunteers
- 83 people
- Sponsor
- Hookipa Biotech GmbH
Cytomegalovirus Infection, Cytomegalovirus Disease
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.
- Trial name
- NCT04129398
- Testing
- Letermovir tablet, Letermovir IV
- Where
- 4 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
CMV, Congenital Cmv
Cytomegalovirus Shedding Characteristics in Pregnant Women
The cCHIPS study is a feasibility study for larger scale multi-centre studies and is designed as a single-centre observational cohort, longitudinal, natural history study.
- Conditions
- CMV, Congenital Cmv, Maternal Infections Affecting Fetus or Newborn, Shedding Virus
- Trial name
- cCHIPS (NCT04021628)
- Testing
- No intervention- not applicable
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- St George's, University of London
Cytomegalovirus Disease, Kidney Transplant Infection
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease…
- Trial name
- NCT02439957
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jazz Pharmaceuticals
HIV Infections, Cytomegalovirus Infections
Valganciclovir to Reduce T Cell Activation in HIV Infection
The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune…
- Trial name
- NCT00264290
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Infections, Cytomegalovirus
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine
The purpose of this study is to evaluate the persistence of the vaccine induced immune responses at Month 48 (Year 4) and Month 60 (Year 5) in healthy subjects who received 3 doses of GSK Biologicals' candidate CMV vaccine…
- Trial name
- NCT01357915
- Testing
- Blood sampling, GSK149203A
- Where
- 2 sites in Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. T-cells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT01646645
- Testing
- CMV-pp65 CTLs
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cytomegalovirus Infections
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
This study will evaluate the safety, tolerability, and immunogenicity of various doses, formulations, and routes of administration of Human Cytomegalovirus (HCMV) vaccine V160 administered in a 3-dose regimen in healthy adults.
- Trial name
- NCT01986010
- Testing
- V160 Low Dose IM, V160 Medium Dose IM, V160 High Dose IM
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Infections
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the standard of care upon initiation of the study, to 12…
- Trial name
- Valgan (NCT00227370)
- Testing
- valganciclovir
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Duke University
CMV Disease
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients.
- Trial name
- NCT03443869
- Testing
- Letermovir, Valganciclovir, Acyclovir (ACV)
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 601 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Infections
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
- Trial name
- NCT00411645
- Testing
- maribavir
- Where
- 97 sites in United States, Belgium and 7 more
- Volunteers
- 681 people
- Sponsor
- Shire
Cytomegalovirus Infections
Evaluation of the Artus® CMV PCR Test
Subjects with symptomatic CMV infection, who are enrolled in this clinical study, will be monitored during antiviral therapy.
- Trial name
- CMV (NCT01034709)
- Where
- 5 sites in United States
- Volunteers
- 111 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Cytomegalovirus (CMV)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting…
- Trial name
- NCT05137717
- Testing
- Maribavir
- Where
- 20 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Takeda
Kidney Transplantation, Cytomegalovirus Infections
A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients.
- Trial name
- NCT01376804
- Testing
- valganciclovir [Valcyte]
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma
- Trial name
- NCT02396134
- Testing
- CMVpp65-A*0201 peptide vaccine, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infections
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
This study will assess the relative bioavailability of ganciclovir from the pro-drug valganciclovir in lung transplant recipients with or without cystic fibrosis.
- Trial name
- NCT00377741
- Testing
- valganciclovir [Valcyte]
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Lung Transplant, CMV
Letermovir for CMV Prevention After Lung Transplantation
This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with…
- Trial name
- NCT05041426
- Testing
- Letermovir, Valganciclovir
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fernanda P Silveira, MD, MS
Infections, Cytomegalovirus, Cytomegalovirus Infections
Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus
This study is designed to evaluate maternal virological and immunological parameters to determine their ability to predict congenital cytomegalovirus (CMV) infection.
- Trial name
- NCT01251744
- Testing
- Blood sample, Cord blood sample, Saliva swab
- Where
- 9 sites in Belgium
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Infections
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens…
- Trial name
- NCT05089630
- Testing
- Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine
- Where
- 18 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline